Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB) and uniQure (QURE).
Credit Suisse analyst Evan Seigerman maintained a Hold rating on Biogen today and set a price target of $270.00. The company’s shares closed last Thursday at $260.88.
According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 35.8% and a 73.8% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Satsuma Pharmaceuticals, Vertex Pharmaceuticals, and Aimmune Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Biogen with a $307.53 average price target, which is a 17.2% upside from current levels. In a report issued on June 22, Barclays also downgraded the stock to Hold with a $280.00 price target.
See today’s analyst top recommended stocks >>
Credit Suisse analyst Martin Auster maintained a Buy rating on uniQure yesterday and set a price target of $76.00. The company’s shares closed last Thursday at $49.05.
According to TipRanks.com, Auster is a 5-star analyst with an average return of 19.9% and a 60.0% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.
uniQure has an analyst consensus of Moderate Buy, with a price target consensus of $66.17, which is a 24.3% upside from current levels. In a report issued on June 9, Mizuho Securities also maintained a Buy rating on the stock with a $90.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.